Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.

The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.

The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

NEW YORK – Catalent and Galapagos on Tuesday said they were partnering to advance Galapagos' decentralized autologous CAR T-cell therapy GLPG5101 in patients with relapsed or refractory non-Hodgkin ...

Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...